369 results on '"Mañosa M"'
Search Results
2. P168 Specialized pro-resolving lipid mediator Resolvin D1 and omega 6 dihomo-γ-linolenic acid are unable to solve inflammation in the creeping fat of patients with severe postoperative recurrence in Crohn's disease
3. P081 The integration of transcriptomic and microbiomic data links several intestinal bacterial families with key biological functions in the development of postoperative recurrence in Crohn's disease
4. P1211 A faecal microbial signature, in combination with faecal calprotectin, to optimise endoscopic activity monitoring in Crohn’s Disease
5. DOP75 Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA
6. Tratamiento de mantenimiento con azatioprina o infliximab en pacientes con colitis ulcerosa corticorrefractarios respondedores a las 3 dosis de inducción de infliximab
7. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry
8. DOP17 HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry
9. OP27 Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
10. P023 Immune-metabolic profiles of creeping fat in relation to degree of severity in Crohn's disease postsurgical recurrence
11. P430 Mesalazine dose modification based on fecal calprotectin levels in ulcerative colitis patients in clinical remission
12. OP26 Impact of telemonitoring on the management of Inflammatory Bowel Disease in Spain: a multicenter TECCU clinical trial
13. OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
14. P386 Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study
15. P634 Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry
16. Requerimientos terapéuticos en el tratamiento de mantenimiento de la proctitis ulcerosa
17. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study
18. N032 Impact of pain due to subcutaneous administration of a biological drug
19. OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry
20. Editorial: therapeutic drug monitoring for anti‐TNF agents—has it all been said?
21. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
22. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
23. P562 Real-life infliximab trough levels among inflammatory bowel disease patients on maintenance therapy: should we redefine therapeutic range based on inflammatory load?
24. P480 Characteristics of drug-induced lupus 2° to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF
25. P367 The availability of infliximab trough levels in IBD patients on maintenance therapy deeply impacts therapeutic decision-making
26. P371 The addition of intravenous, high dose, bolus of methyl-prednisolone increases the early clinical response to oral corticosteroids in moderately active ulcerative colitis. Preliminary results of a prospective, controlled, multicentre, randomised, open-label study
27. P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
28. DOP34 Comparison of the risk of clinical recurrence after ileocolonic resection for Crohn’s Disease for modified Rutgeerts’ score i2a and i2b categories: Individual patient data meta-analysis
29. DOP05 Morbid obesity, a new susceptibility factor for developing Inflammatory Bowel Disease. Results of a population-based study
30. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
31. Noninvasive assessment of liver fibrosis in Crohn's disease patients exposed to methotrexate
32. Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry
33. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients
34. P022 Pathologic involvement of the farnesoid X receptor/fibroblast growth factor 19 axis to the Crohn’s disease early postsurgical recurrence
35. P630 Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)
36. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study
37. P531 SARS-CoV-2 infection in Elderly patients with Inflammatory Bowel Disease with or without immunosuppressants during the first year of the pandemic. An observational, descriptive, cohort study
38. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study
39. FLUOROSCOPY GUIDED POEM IN A SIGMOID ESOPHAGUS
40. ESD USING A DOUBLE BALLOON ENDOLUMENAL INTERVENTIONAL PLATFORM FOR STABILIZATION COMBINING WITH RUBBER BAND CLIP TRACTION
41. P746 Prevalence, features and outcomes of splachnic vein thrombosis in inflammatory bowel disease. A nationwide, retrospective study from the ENEIDA registry
42. P501 Thiopurine withdrawal in patients with Crohn’s disease: the SURESTE study
43. P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study
44. P544 Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry
45. P835 Correlation between microbial markers and faecal calprotectin in IBD patients
46. P774 Low adhesion to latent tuberculosis (TB) screening recommendations in inflammatory bowel disease (IBD) patients: Results of the INFEII registry of GETECCU
47. Endoscopist experience as a risk factor for colonoscopic complications
48. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice
49. Clinical outcome of newly diagnosed Crohnʼs disease: a comparative, retrospective study before and after infliximab availability
50. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.